The landscape of biopharma deals and M&As has seen a transformative shift, with a year-over-year drop in transaction numbers while value has increased. Overall, biopharma deals saw an uptick in value of nearly 6%, and biopharma M&As concurrently soared 80% higher in value than the previous year.
Daiichi Sankyo Co. Ltd. and Kyoto Pharmaceutical Industries Ltd. have identified Kelch-like ECH-associated protein 1 (Keap1)/Nrf2 interaction inhibitors reported to be useful for the treatment of acute lung injury, chronic kidney disease, autism, Alzheimer's disease, dry eye, heart failure, psoriasis and Sjögren's syndrome, among others.
There is increasing evidence on the involvement of Toll-like receptor 7 (TLR7) in the pathogenesis of systemic lupus erythematosus (SLE). At the recent American College of Rheumatology meeting, researchers from Daiichi Sankyo Co. Ltd. presented preclinical data on DS-7011a, a TLR7 antagonist antibody with for the potential treatment of SLE.
GSK plc is the latest pharma giant to bite the “magic bullet” of antibody-drug conjugate (ADC) drugs, promising to pay the Chinese immunotherapy developer Hansoh Pharmaceutical Co. Ltd. $85 million up front and over $1.4 billion in milestone payments in a licensing deal for HS-20089.
Deals involving antibody-drug conjugate (ADC) therapies continue to gain momentum with Daiichi Sankyo Co. Ltd. and Merck & Co. Inc. the latest firms to team up on global development and commercialization activities, as Daiichi offers up rights to three of its potentially first-in-class ADC candidates for $22 billion, making it the largest ADC agreement to date.
GSK plc is the latest pharma giant to bite the “magic bullet” of antibody-drug conjugate (ADC) drugs, promising to pay the Chinese immunotherapy developer Hansoh Pharmaceutical Co. Ltd. $85 million up front and over $1.4 billion in milestone payments in a licensing deal for HS-20089.
Deals involving antibody-drug conjugate (ADC) therapies continue to gain momentum with Daiichi Sankyo Co. Ltd. and Merck & Co. Inc. the latest firms to team up on global development and commercialization activities, as Daiichi offers up rights to three of its potentially first-in-class ADC candidates for $22 billion, making it the largest ADC agreement to date.
Insanity has often been defined as doing the same thing and expecting different results, and Japan seems to be trapped in that rut largely because it can’t seem to do innovation differently, said speakers at the BioJapan 2023 meeting held Oct. 11 in Yokohama, Japan.
Insanity has often been defined as doing the same thing and expecting different results, and Japan seems to be trapped in that rut largely because it can’t seem to do innovation differently, said speakers at the BioJapan 2023 meeting held Oct. 11 in Yokohama, Japan.
Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form the basis of global approval bids, as Astrazeneca plc with Daiichi Sankyo Co. Ltd. unveiled interim results from a study called Tropion-Breast01. Targeting trophoblast cell surface antigen 2, datopotamab deruxtecan (dato) hit the mark in progression-free survival for patients with hormone receptor-positive, HER2-low or negative breast cancer in the study called Tropion-Breast01.
